Overview

Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple Sclerosis

Status:
Completed
Trial end date:
2003-12-01
Target enrollment:
Participant gender:
Summary
The participant will receive weekly intramuscular treatment with AVONEX® (interferon beta 1-a) and bi-monthly high dose intravenous methotrexate with Leucovorin rescue.
Phase:
Phase 4
Details
Lead Sponsor:
MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute
Collaborators:
Biogen
Consultants in Neurology
Treatments:
Interferon beta-1a
Interferon-beta
Interferons
Methotrexate